Table 4.
Joint association of SLC31A1 rs2233914 (G/A) and ABCG2 rs1871744 (A/G) with objective response
| Stratification subgroup | Genotype (SLC31A1—ABCG2)a | Response (CR+PR/SD+PD) | OR (95% CI)b | P valueb |
|---|---|---|---|---|
| All | [G/G] - [A/A+G/G] | 58/215 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 66/257 | 0.93 (0.62-1.41) | 0.740 | |
| [G/G] - [A/G] | 37/137 | 0.96 (0.59-1.57) | 0.875 | |
| [A/G+A/A] - [A/G] | 16/189 | 0.31 (0.17-0.56)c | 1.23×10-4 | |
| Gender | ||||
| Male | [G/G] - [A/A+G/G] | 49/141 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 50/189 | 0.73 (0.45-1.17) | 0.190 | |
| [G/G] - [A/G] | 22/94 | 0.56 (0.31-1.04) | 0.066 | |
| [A/G+A/A] - [A/G] | 10/134 | 0.20 (0.10-0.42) | 2.50×10-5 | |
| Female | [G/G] - [A/A+G/G] | 9/74 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 16/68 | 1.65 (0.64-4.24) | 0.299 | |
| [G/G] - [A/G] | 15/43 | 3.19 (1.22-8.33) | 0.018 | |
| [A/G+A/A] - [A/G] | 6/55 | 0.85 (0.27-2.67) | 0.778 | |
| Age | ||||
| ≤58 | [G/G] - [A/A+G/G] | 23/126 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 28/127 | 1.12 (0.60-2.11) | 0.719 | |
| [G/G] - [A/G] | 22/70 | 1.51 (0.76-3.03) | 0.243 | |
| [A/G+A/A] - [A/G] | 10/96 | 0.54 (0.24-1.23) | 0.141 | |
| >58 | [G/G] - [A/A+G/G] | 35/89 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 38/130 | 0.69 (0.39-1.23) | 0.211 | |
| [G/G] - [A/G] | 15/67 | 0.53 (0.26-1.11) | 0.091 | |
| [A/G+A/A] - [A/G] | 6/93 | 0.16 (0.06-0.41) | 1.46×10-4 | |
| ECOG PS | ||||
| 0-1 | [G/G] - [A/A+G/G] | 53/199 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 64/223 | 1.02 (0.66-1.58) | 0.922 | |
| [G/G] - [A/G] | 31/123 | 0.95 (0.57-1.60) | 0.849 | |
| [A/G+A/A] - [A/G] | 14/171 | 0.30 (0.16-0.57) | 2.44×10-4 | |
| 2 | [G/G] - [A/A+G/G] | 5/12 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 2/29 | 0.04 (0.00-0.53) | 0.014 | |
| [G/G] - [A/G] | 5/12 | 0.47 (0.04-5.36) | 0.546 | |
| [A/G+A/A] - [A/G] | 2/17 | 0.18 (0.01-2.98) | 0.230 | |
| Smoking status | ||||
| Nonsmoker | [G/G] - [A/A+G/G] | 20/103 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 22/100 | 1.15 (0.57-2.32) | 0.703 | |
| [G/G] - [A/G] | 21/57 | 2.06 (1.00-4.28) | 0.052 | |
| [A/G+A/A] - [A/G] | 6/82 | 0.40 (0.15-1.08) | 0.070 | |
| Smoker | [G/G] - [A/A+G/G] | 38/112 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 44/156 | 0.80 (0.47-1.36) | 0.409 | |
| [G/G] - [A/G] | 16/80 | 0.52 (0.26-1.06) | 0.072 | |
| [A/G+A/A] - [A/G] | 10/107 | 0.25 (0.11-0.54) | 4.27×10-4 | |
| TNM stage | ||||
| IIIA | [G/G] - [A/A+G/G] | 9/12 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 9/17 | 0.47 (0.13-1.80) | 0.272 | |
| [G/G] - [A/G] | 6/10 | 0.53 (0.11-2.62) | 0.436 | |
| [A/G+A/A] - [A/G] | 3/13 | 0.24 (0.05-1.24) | 0.088 | |
| IIIB | [G/G] - [A/A+G/G] | 19/72 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 19/63 | 1.20 (0.56-2.60) | 0.637 | |
| [G/G] - [A/G] | 15/32 | 1.66 (0.70-3.93) | 0.247 | |
| [A/G+A/A] - [A/G] | 3/61 | 0.18 (0.05-0.66) | 0.010 | |
| IV | [G/G] - [A/A+G/G] | 30/130 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 38/175 | 0.86 (0.50-1.50) | 0.604 | |
| [G/G] - [A/G] | 16/93 | 0.76 (0.38-1.50) | 0.423 | |
| [A/G+A/A] - [A/G] | 10/115 | 0.38 (0.17-0.82) | 0.013 | |
| Histological type | ||||
| AC | [G/G] - [A/A+G/G] | 24/146 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 24/173 | 0.84 (0.45-1.56) | 0.577 | |
| [G/G] - [A/G] | 19/84 | 1.34 (0.68-2.64) | 0.391 | |
| [A/G+A/A] - [A/G] | 11/131 | 0.50 (0.23-1.07) | 0.072 | |
| SCC | [G/G] - [A/A+G/G] | 20/37 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 24/46 | 0.99 (0.46-2.12) | 0.969 | |
| [G/G] - [A/G] | 15/38 | 0.72 (0.30-1.70) | 0.451 | |
| [A/G+A/A] - [A/G] | 3/34 | 0.14 (0.04-0.53) | 0.004 | |
| Therapy regimens | ||||
| Pt-navelbine | [G/G] - [A/A+G/G] | 21/62 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 28/78 | 0.97 (0.49-1.94) | 0.936 | |
| [G/G] - [A/G] | 17/36 | 1.41 (0.63-3.15) | 0.406 | |
| [A/G+A/A] - [A/G] | 7/53 | 0.33 (0.13-0.87) | 0.025 | |
| Pt-gemcitabine | [G/G] - [A/A+G/G] | 13/54 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 15/61 | 0.90 (0.38-2.17) | 0.820 | |
| [G/G] - [A/G] | 4/29 | 0.52 (0.14-1.89) | 0.323 | |
| [A/G+A/A] - [A/G] | 5/50 | 0.47 (0.15-1.47) | 0.195 | |
| Pt-paclitaxe | [G/G] - [A/A+G/G] | 20/72 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 13/77 | 0.59 (0.25-1.38) | 0.223 | |
| [G/G] - [A/G] | 13/54 | 0.89 (0.38-2.08) | 0.786 | |
| [A/G+A/A] - [A/G] | 3/58 | 0.19 (0.05-0.70) | 0.012 | |
| Pt-docetaxel | [G/G] - [A/A+G/G] | 3/15 | 1.00 (ref) | |
| [A/G+A/A] - [A/A+G/G] | 4/29 | 1.54 (0.16-15.34) | 0.711 | |
| [G/G] - [A/G] | 3/10 | 0.55 (0.06-5.16) | 0.597 | |
| [A/G+A/A] - [A/G] | 1/20 | 0.25 (0.01-4.70) | 0.352 |
a SLC31A1 rs2233914 (G/A) for the study subjects had been genotyped in our previous report (Ref 9).
b Odds ratios (OR) and their 95% confidence intervals (CIs) and P values were calculated with unconditional logistic regression analysis, with adjustment of gender, age, smoking status, ECOG performance status, TNM status, histological types, and treatment regimen.
c Test of interaction for the cohort of all patients with P value being 0.003.